Table 2 Comparison of clinicopathological features between the training set and the validation set.
Characteristics | Training set | Validation set | p value |
|---|---|---|---|
No. patients | n = 545 | n = 136 | |
Age at diagnosis (%) | 0.537 | ||
< 40 | 87 (16.0) | 19 (14.0) | |
40–65 | 349 (64.0) | 94 (69.1) | |
> 65 | 109 (20.0) | 23 (16.9) | |
Race (%) | 0.493 | ||
Black | 134 (24.6) | 40 (29.4) | |
White | 364 (66.8) | 84 (61.8) | |
Other | 47 (8.6) | 12 (8.8) | |
Marital status (%) | 0.338 | ||
Married | 288 (52.8) | 65 (47.8) | |
Single | 257 (47.2) | 71 (52.2) | |
Grade (%) | 1 | ||
I–II | 33 (6.1) | 8 (5.9) | |
III–IV | 512 (93.9) | 128 (94.1) | |
T stage (%) | 0.391 | ||
T1 | 238 (43.7) | 53 (39.0) | |
T2 | 270 (49.5) | 76 (55.9) | |
T3–T4 | 37 (6.8) | 7 (5.1) | |
N stage (%) | 0.771 | ||
N0 | 424 (77.8) | 108 (79.4) | |
N1–N3 | 121 (22.2) | 28 (20.6) | |
ER status (%) | 0.134 | ||
Negative | 349 (64.0) | 97 (71.3) | |
Positive | 196 (36.0) | 39 (28.7) | |
PR status (%) | 0.481 | ||
Negative | 440 (80.7) | 114 (83.8) | |
Positive | 105 (19.3) | 22 (16.2) | |
HER2 status (%) | 0.694 | ||
Negative | 484 (88.8) | 123 (90.4) | |
Positive | 61 (11.2) | 13 (9.6) | |
Subtype (%) | 0.156 | ||
HR−/HER2− | 292 (53.6) | 86 (63.2) | |
HR−/HER2+ | 38 (7.0) | 6 (4.4) | |
HR+/HER2− | 192 (35.2) | 37 (27.2) | |
HR+/HER2+ | 23 (4.2) | 7 (5.1) | |
Surgery (%) | 1 | ||
No/unknown | 11 (2.0) | 3 (2.2) | |
Yes | 534 (98.0) | 133 (97.8) | |
Radiation (%) | 0.443 | ||
No | 266 (48.8) | 72 (52.9) | |
Yes | 279 (51.2) | 64 (47.1) | |
Chemotherapy (%) | 0.784 | ||
No/unknown | 141 (25.9) | 33 (24.3) | |
Yes | 404 (74.1) | 103 (75.7) | |
